Table 5.
Cox proportional hazards univariate modeling for time to treatment failure and overall survival
| Variable | Time to treatment failure | Overall survival | ||
| Hazard ratio (95% CI) | P valuea | Hazard ratio (95% CI) | P valuea | |
| Univariate modeling | ||||
| Age >50 years | 0.59 (0.42–0.83) | 0.0051 | 0.64 (0.46–0.89) | 0.041 |
| Performance status: 0 versus 1 or 2 | 1.30 (0.95–1.78) | 0.11 | 1.41 (1.03–1.94) | 0.031 |
| ER positive | 0.78 (0.56–1.08) | 0.13 | 0.61 (0.43–0.84) | 0.0029 |
| PR positive | 0.72 (0.51–1.00) | 0.53 | 0.71 (0.51–1.00) | 0.049 |
| ER/PR positive | 0.72 (0.51–1.00) | 0.53 | 0.62 (0.44–0.86) | 0.0048 |
| Number of metastatic sites: 0 to 2 versus 3+ | 1.72 (1.03–2.88) | 0.37 | 1.10 (0.66–1.82) | 0.72 |
| Disease-free interval: ≤2 years versus >2 years | 0.72 (0.52–1.00) | 0.49 | 0.81 (0.59–1.12) | 0.20 |
| Prior adjuvant chemotherapy | 0.87 (0.63–1.20) | 0.39 | 0.93 (0.68–1.29) | 0.67 |
| HER2 positive by CB11 | 1.44 (0.97–2.15) | 0.68 | 1.34 (0.91–1.99) | 0.41 |
| HER2 positive by FISH | 1.22 (0.85–1.76) | 0.29 | 1.24 (0.86–1.79) | 0.25 |
| HER2 by HercepTest: 0–1 versus 2–3 | 1.02 (0.73–1.43) | 0.90 | 1.04 (0.74–1.46) | 0.83 |
| HER2 by HercepTest: 0–2 versus 3 | 1.34 (0.91–1.98) | 0.14 | 1.11 (0.76–1.64) | 0.59 |
| Multivariate modeling | ||||
| Age >50 years | 0.99 (0.97–1.00) | 0.045 | 0.99 (0.97–1.00) | 0.10 |
| ER/PR positive | 1.28 (0.89–1.82) | 0.18 | 1.55 (1.08–2.22) | 0.017 |
| HER2 negative on HercepTest: 0–1 versus 2–3 | 0.97 (0.68–1.40) | 0.88 | 0.93 (0.65–1.35) | 0.71 |
aP values were calculated using the log-rank test. CI, confidence interval; ER, estrogen receptor; FISH, fluorescence in situ hybridization; PR, progesterone receptor.